Search - tctmd.com

Displaying 21 - 40 of 54

Sort: Relevancy | Date

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

News Conference News ESC 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

August 30, 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

News Conference News HRS 2020

PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety

May 15, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

News Daily News

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

March 16, 2020

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

News Daily News

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

March 02, 2020

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

February 28, 2020

Year in Review: Digital Health and A-fib Ablation Top 2019 Heart Rhythm News

News Daily News

Year in Review: Digital Health and A-fib Ablation Top 2019 Heart Rhythm News

December 19, 2019

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

News Daily News

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

December 02, 2019

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

News Daily News

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

October 18, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment

News Features

Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment

June 25, 2019

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

January 29, 2019

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

News Daily News

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

Yael L. Maxwell

December 13, 2018

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

September 24, 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.